Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

E. Giovannetti, P.A. Zucali, Y.G. Assaraf, L.G. Leon, K Smid, C. Alecci, F. Giancola, A. Destro, L. Gianoncelli, E. Lorenzi, M. Roncalli, A. Santoro, G.J. Peters

Research output: Contribution to journalArticleAcademicpeer-review

73 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)1542-1553
JournalBritish Journal of Cancer
Issue number10
Publication statusPublished - 2011

Cite this